The MARIPOSA trials - implications for the treatment of EGFR-mutant NSCLC

被引：1
|
作者：
Ardeshir-Larijani, Fatemeh [1 ]
Ramalingam, Suresh S. [1 ]
机构：
[1] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2024年 / 21卷 / 11期
关键词：
D O I：
10.1038/s41571-024-00938-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In the past 2 years, substantial improvements have been made in the management of advanced-stage EGFR-mutant non-small-cell lung cancer. Recent studies have suggested added benefit from the combination of third-generation tyrosine-kinase inhibitors with either chemotherapy or a bispecific antibody targeting EGFR and MET. Herein, we summarize these advances and their implications for clinical practice.
引用
收藏
页码：767 / 768
页数：2
相关论文
共 50 条
  • [21] Patritumab deruxtecan shows activity in EGFR-mutant NSCLC
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2023, 20 : 817 - 817
  • [22] Rociletinib-associated cataracts in EGFR-mutant NSCLC
    Piotrowska, Z.
    Liu, E.
    Varga, A.
    Thakur, M.
    Narayanan, V.
    Liu, S. V.
    Neal, J.
    Spiegel, M.
    Solomon, B.
    Yu, H.
    Ou, S-H. I.
    Papadimitrakopoulou, V. A.
    Gadgeel, S.
    Camidge, D. R.
    Soria, J-C.
    Wakelee, H.
    Goldman, J.
    Kopani, K.
    Rolfe, L.
    Sequist, L. V.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] Overview of current systemic management of EGFR-mutant NSCLC
    Hsu, W. -H.
    Yang, J. C. -H.
    Mok, T. S.
    Loong, H. H.
    ANNALS OF ONCOLOGY, 2018, 29 : I3 - I9
  • [24] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
    Freydman, Jessica
    Henshaw, Lynnette
    Patel, Jasmine V.
    Smith, Claire E.
    Everett, Peter C.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
  • [25] Outcomes of EGFR-mutant NSCLC patients with de novo brain metastases by upfront treatment
    Ma, J.
    Li, Y.
    Lai, G. G. Y.
    Tan, E-H.
    Lim, W. D. T.
    Ang, M-K.
    Ng, Q. S.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Fong, K. W.
    Siow, T. R.
    Thiagarajan, A.
    Yap, S. P.
    Chia, S. H. B.
    Ng, W. L.
    Tan, D. S. W.
    Tan, S. H.
    Tan, W. L.
    Chua, K. L. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S970 - S970
  • [26] Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
    Ruglioni, Martina
    Petrini, Iacopo
    Crucitta, Stefania
    Sbrana, Andrea
    Luculli, Giovanna Irene
    Gol, Leila Sadeghi
    Forte, Carola
    Chella, Antonio
    Rolfo, Christian
    Danesi, Romano
    Del Re, Marzia
    TRANSLATIONAL ONCOLOGY, 2025, 52
  • [27] Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
    Gettinger, Scott
    Hellmann, Matthew D.
    Chow, Laura Q. M.
    Borghaei, Hossein
    Antonia, Scott
    Brahmer, Julie R.
    Goldman, Jonathan W.
    Gerber, David E.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott A.
    Young, Tina C.
    Li, Xuemei
    Geese, William J.
    Rizvi, Naiyer
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1363 - 1372
  • [28] Befotertinib-a viable alternative in EGFR-mutant advanced NSCLC?
    Menis, Jessica
    Remon, Jordi
    LANCET RESPIRATORY MEDICINE, 2023, 11 (10): : 857 - 859
  • [29] What new therapeutic targets exist for EGFR-mutant NSCLC?
    Rosell, Rafael
    LANCET ONCOLOGY, 2014, 15 (11): : 1184 - 1185
  • [30] EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022
    Girard, Nicolas
    Basse, Clemence
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1115 - 1125
12345